COVID-Flu Combination Vaccine Performs Well in Clinical Trial, Moderna Says

Pharmaceutical company says the combo shot, if approved, ‘could improve compliance.’

Moderna's headquarters in Cambridge, Mass., on May 8, 2020. Maddie Meyer/Getty Images

A combination vaccine that targets both COVID-19 and influenza did well in a phase 3 clinical trial, Moderna said on June 10.

Participants who received the combination shot had at least the same level of immune response as comparison cohorts, according to the Massachusetts-based pharmaceutical company, which produced one of the most widely used COVID-19 vaccines in the world.